Cargando…

Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series

Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR)(+), human epidermal growth factor receptor (HE...

Descripción completa

Detalles Bibliográficos
Autores principales: Schettini, Francesco, Santo, Irene De, Rea, Carmen G., Viggiani, Martina, Buono, Giuseppe, Angelis, Carmine De, Cardalesi, Cinzia, Lauria, Rossella, Giuliano, Mario, Forestieri, Valeria, Thomas, Guglielmo, Maione, Pierfrancesco, Limite, Gennaro, Accurso, Antonello, Malorni, Luca, Placido, Sabino De, Arpino, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087462/
https://www.ncbi.nlm.nih.gov/pubmed/32257203
http://dx.doi.org/10.3892/mco.2020.2016
_version_ 1783509336493916160
author Schettini, Francesco
Santo, Irene De
Rea, Carmen G.
Viggiani, Martina
Buono, Giuseppe
Angelis, Carmine De
Cardalesi, Cinzia
Lauria, Rossella
Giuliano, Mario
Forestieri, Valeria
Thomas, Guglielmo
Maione, Pierfrancesco
Limite, Gennaro
Accurso, Antonello
Malorni, Luca
Placido, Sabino De
Arpino, Grazia
author_facet Schettini, Francesco
Santo, Irene De
Rea, Carmen G.
Viggiani, Martina
Buono, Giuseppe
Angelis, Carmine De
Cardalesi, Cinzia
Lauria, Rossella
Giuliano, Mario
Forestieri, Valeria
Thomas, Guglielmo
Maione, Pierfrancesco
Limite, Gennaro
Accurso, Antonello
Malorni, Luca
Placido, Sabino De
Arpino, Grazia
author_sort Schettini, Francesco
collection PubMed
description Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR)(+), human epidermal growth factor receptor (HER)2(-) metastatic breast cancer. There is evidence that palbociclib may reverse endocrine therapy resistance and that it may also be added to ongoing endocrine therapy beyond progression to obtain clinical benefit. The aim of the present study was to explore this possibility in 5 patients who received palbociclib + fulvestrant following disease progression while under treatment with fulvestrant alone. The median progression-free survival was not reached during a median follow-up of 25 months, and the most frequent best response was stable disease. Three patients remained under treatment on the last re-evaluation. All patients had highly endocrine-sensitive disease and had previously received fulvestrant for ≥12 months. The hypothesis that a selected subpopulation of patients with HR(+)/HER2(-) metastatic breast cancer may benefit from the addition of palbociclib to ongoing endocrine therapy beyond disease progression merits further investigation.
format Online
Article
Text
id pubmed-7087462
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70874622020-04-02 Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series Schettini, Francesco Santo, Irene De Rea, Carmen G. Viggiani, Martina Buono, Giuseppe Angelis, Carmine De Cardalesi, Cinzia Lauria, Rossella Giuliano, Mario Forestieri, Valeria Thomas, Guglielmo Maione, Pierfrancesco Limite, Gennaro Accurso, Antonello Malorni, Luca Placido, Sabino De Arpino, Grazia Mol Clin Oncol Articles Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR)(+), human epidermal growth factor receptor (HER)2(-) metastatic breast cancer. There is evidence that palbociclib may reverse endocrine therapy resistance and that it may also be added to ongoing endocrine therapy beyond progression to obtain clinical benefit. The aim of the present study was to explore this possibility in 5 patients who received palbociclib + fulvestrant following disease progression while under treatment with fulvestrant alone. The median progression-free survival was not reached during a median follow-up of 25 months, and the most frequent best response was stable disease. Three patients remained under treatment on the last re-evaluation. All patients had highly endocrine-sensitive disease and had previously received fulvestrant for ≥12 months. The hypothesis that a selected subpopulation of patients with HR(+)/HER2(-) metastatic breast cancer may benefit from the addition of palbociclib to ongoing endocrine therapy beyond disease progression merits further investigation. D.A. Spandidos 2020-05 2020-03-11 /pmc/articles/PMC7087462/ /pubmed/32257203 http://dx.doi.org/10.3892/mco.2020.2016 Text en Copyright: © Schettini et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Schettini, Francesco
Santo, Irene De
Rea, Carmen G.
Viggiani, Martina
Buono, Giuseppe
Angelis, Carmine De
Cardalesi, Cinzia
Lauria, Rossella
Giuliano, Mario
Forestieri, Valeria
Thomas, Guglielmo
Maione, Pierfrancesco
Limite, Gennaro
Accurso, Antonello
Malorni, Luca
Placido, Sabino De
Arpino, Grazia
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
title Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
title_full Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
title_fullStr Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
title_full_unstemmed Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
title_short Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
title_sort palbociclib added to ongoing endocrine therapy for hormone receptor-positive her2-negative metastatic breast cancer: a case report series
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087462/
https://www.ncbi.nlm.nih.gov/pubmed/32257203
http://dx.doi.org/10.3892/mco.2020.2016
work_keys_str_mv AT schettinifrancesco palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT santoirenede palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT reacarmeng palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT viggianimartina palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT buonogiuseppe palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT angeliscarminede palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT cardalesicinzia palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT lauriarossella palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT giulianomario palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT forestierivaleria palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT thomasguglielmo palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT maionepierfrancesco palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT limitegennaro palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT accursoantonello palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT malorniluca palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT placidosabinode palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries
AT arpinograzia palbociclibaddedtoongoingendocrinetherapyforhormonereceptorpositiveher2negativemetastaticbreastcanceracasereportseries